The COMMAND clinical trial involves the use of Verastem’s experimental drug VS-6063 in patients with malignant pleural mesothelioma. The primary endpoints of COMMAND are progression free survival (PFS) and overall survival (OS). VS-6063 targets cancer stem cells which are an underlying cause of tumor progression and recurrence.
In this January 8, 2015 corporate press release, “Verastem Provides Year-End 2014 Update and Outlook for 2015”, the drug company let us know that things are progressing relatively well for the COMMAND study:
We currently remain on track to complete enrollment by the end of 2015. We are seeing activity of VS-6063 across multiple tumor types, including mesothelioma, ovarian cancer, and also now in advanced non-small cell lung cancer. These results continue to increase our confidence in the potential of a successful outcome from COMMAND. Our goal is to achieve the first approval of VS-6063 in mesothelioma and then to broaden its use to many major cancers such as lung, ovarian and breast cancer [said Robert Forrester, President and Chief Executive Officer of Verastem.]…
“The signals of clinical activity and long-term tolerability that we are seeing across the VS-6063 program are encouraging,” said Dr. Joanna Horobin, Verastem Chief Medical Officer.
We will continue to monitor the COMMAND study being conducted for Verastem’s VS-6063 drug and watch of other clinical trials that involve possible future malignant mesothelioma treatments.
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.